

ABBREVIATED CURRICULUM VITAE

Leigh Ann Burns Naas, PhD DABT ATS ERT

EDUCATION AND CERTIFICATION

- 2012 – present UK Register of Toxicologists (European Registered Toxicologist)
2010 – present Fellow, Academy of Toxicological Sciences
1997 – present Diplomate, American Board of Toxicology (recertified 2008, 2013, 2018)
- 06/92 – 10/94 Postdoctoral Research Fellow, Signal Transduction/T Cell Activation
Department of Immunology, Mayo Clinic and Foundation, Rochester, MN
Postdoctoral Advisor: Dr. Robert T. Abraham
- 1988 – 1992 Ph.D. Pharmacology and Toxicology, Medical College of Virginia, Richmond, VA
Advisor: Dr. Albert E. Munson
- 1982 – 1986 B.S. General Biology
Millsaps College, Jackson, MS

EMPLOYMENT

Gilead Sciences, Inc.

Nonclinical Safety & Pathobiology
Foster City, CA

12/11 – present Vice President

Pfizer, Inc.

Drug Safety Research & Development
San Diego, CA

07/06 – 12/11 Senior Director/Research Fellow
11/03 – 07/06 Associate Research Fellow
12/01 – 11/03 Manager, Non-Clinical Drug Safety
01/09 – 12/11 Global Therapeutic Area Leader – Oncology
01/09 – 12/09 Interim DSRD Therapeutic Area Leader – Vaccines
07/07 – 01/09 DSRD Point of Contact to Vaccines Research
07/06 – 07/07 Development and Regulatory Strategy Lead
01/06 – 07/06 Global Therapeutic Area Leader – Infectious Disease
11/03 – 12/05 Site Therapeutic Area Leader – Antiviral Drugs

Dow Corning Corporation

Environment, Health, and Safety
Midland, MI

01/00 – 12/01 Senior Toxicology Specialist
10/94 – 12/99 Toxicology Specialist
08/00 – 12/01 Leader – HERA-Americas Health Group, Health, Environmental,
and Regulatory Affairs
09/96 – 10/97 Supervisor, Immunotoxicology Laboratory

University of Mississippi Medical Center
Department of Anatomy
Jackson, MS

07/86 – 08/88 Research Assistant
Supervisor: John D. Porter , PhD
Research Focus: Neuroanatomical tract tracing of visual pathways in primate brain

AWARDS AND HONORS

NIEHS Predoctoral Trainee (1989-1992)
Society of Toxicology Graduate Research Award in Immunotoxicology (1990)
American College of Toxicology Student Travel Award (1990)
Society of Toxicology Graduate Fellowship Award, Finalist (1991)
John C. Forbes Graduate Student Research Honors Colloquium (1991)
Anthony J. Ambrose Award for Outstanding Graduate Student in Pharmacology & Toxicology (1991)
Lauren A. Woods Award for Research Excellence in Pharmacology & Toxicology (1991)
Society of Toxicology Student Travel Award (1992)
PHS Postdoctoral Trainee (1992-1993)
Recipient, Individual NRSA (1994-1996)
Diplomate, American Board of Toxicology (1997-present)
Society of Toxicology Colgate-Palmolive Visiting Professorship in *In Vitro* Toxicology (1998)
Dow Corning StARS Program for Outstanding Contributions to the Corporation (2000-2001)
W.E. Upjohn Award for Contributions to the Community (2004)
Pfizer Product Award (Eraxis™/Ecalta™; 2007)
President's Award (American College of Toxicology), Best Paper in *International Journal of Toxicology*
Pfizer Individual Performance Awards (2005, 2005, 2007, 2010)
Pfizer Team Award (2010)
Fellow, Academy of Toxicological Sciences (2010)
UK Register of Toxicologists (European Registered Toxicologist) (2012)
Gilead Key Contributor Award (2013, 2014, 2015, 2016, 2017, 2018)

PROFESSIONAL ACTIVITIES

Developed/Co-developed 22 symposia, workshops, or continuing education courses for: the International Life Sciences Institute / Health and Environmental Sciences Institute (Washington, DC), Charles River Laboratories Biotechnology Symposium, American College of Toxicology, and Society of Toxicology.

Forty-three (43) Invited Speaker presentations on topics including: regulatory toxicology, immunotoxicology, developmental immunotoxicology, oncology drug development, biopharmaceutical drug development, vaccine and adjuvant safety, combination toxicology testing, and career development.

1995-1997 Affiliate Assistant Professor, Dept. Pharmacology & Toxicology, Medical College of Virginia
1995-1996 International Society for the Study of Xenobiotics
1995-2018 American Association of Immunologists (Full Member)
1997 American Chemistry Council, Immunotoxicity Team
1999-2001 American Chemical Society
2001-2003 Drug Information Association

2001-2011 International Life Sciences Institute / Health and Environmental Sciences Institute, Immunotoxicology Technical Committee (ITC)

2003-2008 Clinical Associate Professor, College of Pharmacy, University of New Mexico

2007-2011 International Society for Biological Therapy of Cancer (Full Member)

2012-2016 Genetic Toxicology Association (Member)

2009-present Society of Toxicologic Pathology (Associate Member)

2012-present Safety Pharmacology Society (Member)

2011-present British Toxicology Society (Member)

2007-present American Association of Cancer Research (Full Member)

2007-present American Society of Clinical Oncology (Affiliate Member)

1997-present American Board of Toxicology (Diplomate)

2011-2015 Board of Directors

2010-present Academy of Toxicological Sciences (Fellow)

2013-2016 Board of Directors

2016-2017 Vice-President

2017-2018 President

2018-2019 Past-President

2013-present International Consortium for Innovation and Quality in Pharmaceutical Drug Development

2013-present Board of Directors

2013-2016 DruSafe

1995-present American College of Toxicology (ACT; Full Member)

2001-2003 Councilor and Co-Chair, Education Committee

2004 Vice-President and Chair, Awards Committee

2005 President-Elect and Chair, Program Committee

2006 President

2007 Past-President and Chair, Nominating and Outreach Committees

2011-2013 Awards Committee

1995-present Society of Toxicology (SOT; Full Member)

2005-2007 Continuing Education Committee (appointed)

2009-2013 Scientific Program Committee (appointed)

2013-2014 Secretary-Elect

2014-2016 Secretary

2016-2017 Vice President-Elect

2017-2018 Vice President

2018-2019 President (beginning May 1, 2018)

2019-2020 *Past President (beginning May 1, 2019)*

SOT Specialty Section and Special Interest Group Participation

1995-present Immunotoxicology Specialty Section

1999-2002 Awards Committee

2001-2002 Program Committees

2004-2006 Program Committee

2008-2009 Vice-President Elect and Chair, Program Committee

2009-2010 Vice-President

2010-2011 President and Chair, Nominating Committee

2011-2012 Past-President

2017-2018 Awards Committee

2007-present Women in Toxicology Special Interest Group

2009-2011 Councilor and Chair, Awards Committee

2009-present Biotechnology Specialty Section (charter member)
 2010-2011 Councilor
 2010-2012 Specialty Section Collaboration and Communication Committee (elected),
 Chair

SOT Regional Chapter Participation

1995-2001 Michigan Regional Chapter
 1997-1999 Councilor
 2002-2011 Southern California Regional Chapter
 2012-present Northern California Regional Chapter

PROGRAMMATIC PEER REVIEW AND EXPERT WORKING GROUPS

American Chemistry Council (ACC) Request for Proposal on Developmental Immunotoxicology (2001)
 NIEHS Board of Scientific Review, Ad Hoc Reviewer, Laboratory of Molecular Toxicology (2002)
 Covance Laboratories, Immunotoxicology Expert Working Group (2012)
 National Toxicology Program (NTP) Laboratory Report Peer Reviews:
 Range-Finding Report: Immunotoxicity of Hexavalent Chromium in Female B6C3F1 Mice (2015)
 Range-Finding Report: Immunotoxicity of Hexavalent Chromium in Female F344 Rats (2015)
 National Centre for the Replacement, Refinement, and Reduction of Animals in Research (NC3Rs) and
 Association of British Pharmaceutical Industry (APBI) International Expert Working Group on the
 Utility of a Second Species in Regulatory Toxicology (2017)

EDITORIAL ACTIVITIES

2009-present Editorial Board, *International Journal of Toxicology*
 2013-2015 Editorial Board, *Encyclopedic Reference of Immunotoxicology 2nd Edition*, (H.-W.,
 Vohr, ed.), Springer-Verlag, Heidelberg, Germany
 2013-2016 Editorial Board - Associate Editor, *Toxicology Reports*
 2013-present Editorial Board, *Journal of Immunotoxicology*
 2015-present Editorial Board, *Comprehensive Toxicology 3rd Edition*, (C.A. McQueen, Editor-in-
 Chief), Volume Editor, *Immune System*
 2015-present Editorial Board, *Comprehensive Toxicology 3rd Edition*, (C.A. McQueen, Editor-in-
 Chief), Volume Editor, *Hematopoietic System*

Ad Hoc Reviewer: *Environmental Research*
Food and Chemical Toxicology
Human and Experimental Toxicology
Inhalation Toxicology
Journal of Developmental Origins of Health and Disease
Journal of Innate Immunity
Journal of Pharmacology and Experimental Therapeutics
Life Sciences
Regulatory Toxicology and Pharmacology
Toxicology
Toxicology and Applied Pharmacology
Toxicology Mechanisms and Methods
Toxicological Sciences

PUBLICATIONS

1. Porter, J.D., D.P. Edney, E.J. McMahon, and L.A. Burns. Extraocular myotoxicity of the retrobulbar anesthetic bupivacaine hydrochloride. *Invest. Ophthalmol. Visual Sci.* 29:163-174, 1988.
2. Porter, J.D., L.A. Burns, and E.J. McMahon. Denervation of primate extraocular muscles: A pattern of structural changes that is unique among mammalian skeletal muscle. *Invest. Ophthalmol. Visual Sci.* 30:214-228, 1989.
3. Porter, J.D., L.A. Burns, and P.J. May. Morphological substrate of eyelid movements: Innervation and structure of primate levator palpebrae superioris and orbicularis oculi. *J. Comp. Neurol.* 287 (1): 64-81, 1989.
4. Sikorski, E.E., L.A. Burns, M.L. Stern, M.I. Luster, and A.E. Munson. Splenic cell targets in gallium arsenide-induced suppression of the primary antibody response. *Toxicol. Appl. Pharmacol.* 110:129-142, 1991.
5. Sikorski, E.E., L.A. Burns, K.L. McCoy, M. Stern, and A.E. Munson. Suppression of splenic accessory cell function in mice exposed to gallium arsenide. *Toxicol. Appl. Pharmacol.* 110:143-156, 1991.
6. Burns, L.A., E.E. Sikorski, J. Saady, and A.E. Munson. Evidence for arsenic as the primary immunosuppressive component of gallium arsenide. *Toxicol. Appl. Pharmacol.* 110:157-169, 1991.
7. Burns, L.A., L.F. Butterworth, and A.E. Munson. Reversal of gallium arsenide-induced suppression of the antibody response by a mixed disulfide metabolite of *meso*-2,3-dimercaptosuccinic acid. *J. Pharmacol. Exp. Therap.* 264(2):695-700, 1993.
8. Burns, L.A. and A.E. Munson. Reversal of gallium arsenide-induced suppression of the AFC response by vehicle supernatants. I. Pharmacokinetics following *in vitro* and *in vivo* exposure. *J. Pharmacol. Exp. Therap.* 265(1):144-149, 1993a.
9. Burns, L.A. and A.E. Munson. Reversal of gallium arsenide-induced suppression of the AFC response by vehicle supernatants. II. Nature and identification of reversing factors. *J. Pharmacol. Exp. Therap.* 265(1):150-158, 1993b.
10. Burns, L.A. and A.E. Munson. Gallium arsenide selectively inhibits T cell proliferation and alters expression of CD25 (IL-2R/p55). *J. Pharmacol. Exp. Therap.* 265(1):178-186, 1993c.
11. Burns, L.A., J.A. McCay, R. Brown, and A.E. Munson. Arsenic in the sera of gallium arsenide-exposed mice inhibits bacterial growth and increases host resistance. *J. Pharmacol. Exp. Therap.* 265(2):795-800, 1993.
12. Berggren, M.M., Burns, L.A., Abraham, R.T., and Powis, G. Inhibition of protein tyrosine phosphatase by the antitumor agent gallium nitrate. *Cancer Res.* 53(8):1862-1866, 1993.
13. Secrist, J.P., Burns, L.A., Karnitz, L., Koretsky, G., and R.T. Abraham. Stimulatory effects of the protein tyrosine phosphatase inhibitor pervanadate on T cell activation events. *J. Biol. Chem.* 268(8):5886-5893, 1993.

14. Burns, L.A., Karnitz, L.M., Sutor, S.L., and R.T. Abraham. Interleukin-2-induced tyrosine phosphorylation of p52^{shc} in T lymphocytes. *J. Biol. Chem.* 268(24):17659-17661, 1993.
15. Burns, L.A., Spriggs, T.L., Fuchs, B.A., and A.E. Munson. Gallium arsenide-induced increase in serum corticosterone is not responsible for suppression of the IgM antibody response. *J. Pharmacol. Exp. Therap.* 268:740-746, 1994.
16. Abraham, R.T., Karnitz, L.M., Burns, L.A., and Brunn, G. Proximal signals and the control of S-phase entry in interleukin-2-stimulated T lymphocytes. *Advances in Experimental Medicine and Biology* 365:197-210, 1994.
17. Burns, L.A., Bradley, S.G., White, K.L., McCay, J. A., Fuchs, B.A., Stern, M., Brown, R.D., Musgrove, D.L., Holsapple, M.P., Luster, M.I., and A.E. Munson. Immunotoxicology of Nitrobenzene in Female B6C3F1 Mice. *Drug and Chemical Toxicol.* 17(3):271-315, 1994.
18. Burns, L.A., Bradley, S.G., White, K.L., McCay, J. A., Fuchs, B.A., Stern, M., Brown, R.D., Musgrove, D.L., Holsapple, M.P., Luster, M.I., and A.E. Munson. Immunotoxicology of 2,4-Diaminotoluene in Female B6C3F1 Mice. *Drug and Chemical Toxicol.* 17(3):317-358, 1994.
19. Burns, L.A., Bradley, S.G., White, K.L., McCay, J. A., Fuchs, B.A., Stern, M., Brown, R.D., Musgrove, D.L., Holsapple, M.P., Luster, M.I., and A.E. Munson. Immunotoxicology of Nitrotoluenes in Female B6C3F1 Mice. I. Para-nitrotoluene *Drug and Chemical Toxicol.* 17(3):359-399, 1994.
20. Burns, L.A., Bradley, S.G., White, K.L., McCay, J. A., Fuchs, B.A., Stern, M., Brown, R.D., Musgrove, D.L., Holsapple, M.P., Luster, M.I., and A.E. Munson. Immunotoxicology of Nitrotoluenes in Female B6C3F1 Mice. II. Meta-nitrotoluene *Drug and Chemical Toxicol.* 17(3):401-436, 1994.
21. Karnitz, L.M., Burns, L.A., Sutor, S.L., and R.T. Abraham. Interleukin-2 triggers a novel phosphatidylinositol 3-kinase-dependent MEK activation pathway. *Molec. Cell. Biol.* 15:3049-3057, 1995.
22. Burns, L.A., Duwe, R.L., Jovanovic, M.L., Seaton, T.D., Jean, P.J., Gallavan, R.G., Butterworth, L.F., and White, Jr., K.L. Development and validation of the antibody-forming cell response as an immunotoxicological endpoint in the guinea pig. *Toxicology Methods* 6(4):193-212, 1996.
23. Burns-Naas, L.A., Mast, R.W., Klykken, P.C, McCay, J.A., White, Jr., K.L., Mann, P.C., and Naas, D.J. Toxicology and humoral immunity assessment of decamethylcyclopentasiloxane (D₅) following a 28-day whole body inhalation exposure in Fischer 344 rats. *Toxicological Sciences* 43:28-38, 1998.
24. Burns-Naas, L.A., Mast, R.W., Meeks, R.G., Mann, P.C., and Thevenaz, Ph. Inhalation toxicology of decamethylcyclopentasiloxane (D₅) following a 3-month nose-only exposure in Fischer 344 rats. *Toxicological Sciences* 43:230-240, 1998.
25. Klykken, P.C., Galbraith, T.W., Kolesar, G.B., Woolhiser, M.R., Elwell, M., Burns-Naas, L.A., Mast, R.W., McCay, J.A., White, Jr., K.L., and Munson, A.E. Toxicology and humoral immunity

assessment of octamethylcyclotetrasiloxane (D₄) following a 28-day whole body vapor inhalation exposure in Fischer 344 rats. *Drug and Chemical Toxicology* 22(4): 655-677, 1999.

26. Jovanovic, M.L., Seaton, T.D., Gallavan, R.H., Jr., and Burns-Naas, L.A. Immunotoxicology sample longevity: phenotypic analysis and the NK assay. *Toxicology Methods* 9:1-13, 1999.
27. McKim, J.M., Chouduri, S., Wilga, P.C., Madan, A., Burns-Naas, L.A., Gallavan, R.H., Mast, R.W., Naas, D.J., Parkinson, A., and R.G. Meeks. Induction of hepatic xenobiotic metabolizing enzymes in female Fischer 344 rats following repeated inhalation exposure to decamethylcyclopentasiloxane (D₅). *Toxicological Sciences* 50:10-19, 1999.
28. Burns-Naas, L.A., Meeks, R.G., Kolesar, G.B., Mast, R.W., Elwell, M.R., Hardisty, J.F., and Thevanaz, P. Inhalation toxicology of octamethylcyclotetrasiloxane (D₄) following a 3-month nose-only exposure in Fischer 344 rats. *International Journal of Toxicology* 21(1):39-53, 2002.
29. Burns-Naas, L.A., Webber, S., Stump, D.G., Holson, J.F., Masarjian, L., and Zorbas, M. Absence of embryo-fetal toxicity in rats or rabbits following repeated oral dosing with nelfinavir. *Regulatory Toxicology and Pharmacology* 38(3):291-303, 2003a.
30. Burns-Naas, L.A., Stump, D.G., Webber, S., Holson, J.F., Masarjian, L., Furman, G., and Zorbas, M. Absence of developmental and reproductive toxicity in rats following repeated oral dosing with nelfinavir. *Regulatory Toxicology and Pharmacology* 38(3):304-316, 2003b.
31. Holsapple, M.P., Paustenbach, D.J., Charnley, G., West, L.J., Luster, M.I., Dietert, R.R., and Burns-Naas, L.A. . Workshop Summary: Children's Health – What's so Special about the Developing Immune System? *Toxicology and Applied Pharmacology* 199(1):61-70, 2004.
32. Holsapple, M.P., Burns-Naas, L.A., Hastings, K., Ladics, G.S., Lavin, A.L., Makris, S., Yang, Y., and Luster, M.I. A testing framework for developmental immunotoxicology (DIT): roundtable discussion. *Toxicological Sciences*, 83:18-24, 2005.
33. Burns-Naas, L.A., White, Jr., K.L., McCay, J.A., Ivett, J.L., Webber, S., and Zorbas, M. Immunotoxicity evaluation of nelfinavir in rats. *Human and Experimental Toxicology* 24(2):67-78, 2005.
34. Patick, A.K., Brothers, M., Maldonado, F., Binford, S., Maldonado, O., Fuhrman, S., Petersen, A., Smith III, G.J., Zalman, L., Burns-Naas, L.A., and Tran, J. *In vitro* antiviral activity and human single-dose pharmacokinetics of a novel, orally bioavailable inhibitor of human rhinovirus 3C protease. *Antimicrobial Agents and Chemotherapy* 49(6):2267-2275, 2005.
35. Burns-Naas, L.A. Book Review: *Developmental Immunotoxicology*. S.D. Holladay, Editor. *International Journal of Toxicology* 24:283-284, 2005.
36. Burns-Naas, L.A., Lee, C., Ahern, L. Webber, S., and Zorbas, M.. Lack of respiratory and contact sensitizing potential of the intranasal drug candidate rupintrivir (AG7088): A weight-of-the-evidence evaluation. *Journal of Immunotoxicology* 2(3):123-139, 2005.

37. Ladics, G.S., Chapin, R.E., Hastings, K.L., Holsapple, M.P., Makris, S.L., Sheet, L.P., Woolhiser, M.R., and Burns-Naas, L.A. Developmental toxicology evaluations – issues with including neurotoxicology and immunotoxicology assessments in reproductive toxicology studies. *Toxicological Sciences* 88(1):24-29, 2005.
38. Burns-Naas, L.A., M. Zorbas, Jessen, B., Evering, W., Stevens, G., Ivett, J.L., Ryan, T.E., Chen, M., Furman, G., Wu, E., Shetty, B., Webber, S., Theiss, J., Gasser, R., and M. McClain. Increase in thyroid follicular cell tumors in nelfinavir-treated rats observed in a 2-year carcinogenicity study is consistent with a rat-specific mechanism of thyroid neoplasia. *Human and Experimental Toxicology* 24(12):643-654, 2005.
39. Burns-Naas, L.A., Dearman, R.J., Germolec, D., Kaminski, N.E., Kimber, I., Ladics, G.S., Luebke, R., Pfau, J., and Pruett, S.B. Invited Review: “Omic” technologies and the immune system. *Toxicology Mechanisms and Methods* 16:101-119, 2006.
40. Burns-Naas, L.A., Hastings, K., Ladics, G.S., Makris, S., Parker, G., and Holsapple, M.P. Invited Review. What’s so special about the developing immune system? *International Journal of Toxicology* 27(2):223-254, 2008.
41. Piccotti, J.R., Lebrec, H.N., Evans, E., Herzyk, D.J., Hastings, K.L., Burns-Naas, L.A., Gourley, I.S., Wierda, D., and Kawabata, T.T. Summary of a workshop on nonclinical and clinical immunotoxicity assessment of immunomodulatory drugs. *Journal of Immunotoxicology* 6(1):1-10, 2009.
42. Burns-Naas, L.A. Submitting More Competitive Session Proposals. Society of Toxicology *Communique*’ (online at https://www.toxicology.org/ai/pub/SI11/SI11_proposals.asp).
43. Cappon GD, Chapin RE, Hurtt ME, Wajnrajch MP, Burns-Naas LA. Impaired reproduction in adult male, but not female, rats following juvenile treatment with the aromatase inhibitor, exemestane. *Birth Defects Research, Part B: Developmental and Reproductive Toxicology*. 92(4):304-313, 2011.
44. Turteltaub, K., Davis, M., Burns-Naas, L.A., Lawton, M.P., Clark, A., and Reynolds, J.A. Identification and elucidation of the biology of adverse events: the challenges of safety assessment and translational medicine. *Clinical Cancer Research* 17(21): 6641-6645, 2011.
45. Buckley, L.A., Chapman, K., Burns-Naas, L.A., Todd, M., Martin, P.L., and Lansita, J.A. Considerations regarding nonhuman primate use in safety assessment of biopharmaceuticals. *International Journal of Toxicology*, 30(5) 583-590, 2011.
46. Pandher, K., Leach, M.R., and Burns-Naas, L.A. Appropriate use of recovery groups in nonclinical toxicity studies: value in a science-driven case-by-case approach. *Veterinary Pathology*, 49(2):357-61, 2012.
47. Collinge, M., Burns-Naas, L.A., Chellman, G., Kawabata, T.T., Komacсар, W., Piccotti, J.R., Shenton, J., and Wierda, D. Developmental immunotoxicity (DIT) testing of pharmaceuticals: current practices, the state of the science, knowledge gaps, and recommendations. *Journal of Immunotoxicology*, 9(2):210-230, 2012.
48. Torti, V., Wojciechowicz, D., Hu, W., John-Baptiste, A., Evering, W., Troche, G., Marroquin, L., Smeal, T., Yamakazi, S., Palmer, C.L., Burns-Naas, L.A., and Bagrodia, S. Epithelial tissue

hyperplasia induced by the RAF inhibitor PF-04880594 is attenuated by a clinically well-tolerated dose of the MEK inhibitor PD-0325901. *Molecular Cancer Therapeutics* 11(10):1-10, 2012.

49. McKarns, S.C., Miller, P.G., Palmer, R.K., Pfau, J.C., Raman, P., Regal, J.F., Rodgers, K.E., Schondelmeyer, R.S., Zhang, X., Cohen, M.D., Dean, J.H., Franko, J., Kerkvliet, N.I., Laiosa, M.D., Lawrence, B.P., Luebke, R.W., Luster, M.I., Bonn, M.B., and Burns-Naas, L.A. Immunotoxicology: Fifty years of global scientific progress. *Journal of Immunotoxicology* 9(4):339-340, 2012.
50. Heyen, J.R., Hu, W., Jamieson, J., Thibault, S., Batugo, M., Loi, C.-M., Burns-Naas, L.A., McHarg, A.D., and Jessen, B. Cardiovascular differentiation of imatinib and bosutinib in the rat. *International Journal of Hematology* 98(5):597-607, 2013.
51. Aguirre, S.A., Lui, L., Hosea, N.A., Scott, W., May, J.R., Burns-Naas, L.A., Randolph, S., Denlinger, R.H., and Han, B. Intermittent oral co-administration of a gamma secretase inhibitor with dexamethasone mitigates intestinal goblet cell hyperplasia in rats. *Toxicologic Pathology* 42(2):422-433 2014.
52. Sewell, F., Chapman, K., Baldrick, P., Grewster, D., Broadmeadow, A., Brown, P., Burns-Naas, L.A., Clarke, J., Constan, A, Couch, J., Czupalla, O., Danks, A., DeGeorge, J., De Hann, L., Hettinger, K., Hill, M., Festag, M., Jacobs, A., Jacobson-Kram, D., Kopytek, S., Lorenz, H., Moesgaard, S.G., Moore, E., Pasanen, M., Perry, R., Ragan, I., Robinson, S., Schmitt, P., Short, B., Silva Lima, B., Smith, D., Sparrow, S., van Bekkum, Y., and Jones, D. Recommendations from a global cross-company data sharing initiative on the incorporation of recovery phase animals in safety assessment studies to support first-in-human clinical trials. *Regulatory Toxicology and Pharmacology* 70(1):413-429, 2014.

BOOKS

1. Volume 11: *Immune System Toxicology* (L.A. Burns-Naas, Volume Editor.), In. *Comprehensive Toxicology, Third Edition* (C.A. McQueen, Editor-in Chief), Elsevier Ltd, Oxford, UK, 2018.
2. Volume 12: *Hematopoietic System Toxicology* (L.A. Burns-Naas, Volume Editor.), In. *Comprehensive Toxicology, Third Edition* (C.A. McQueen, Editor-in Chief), Elsevier Ltd., Oxford, UK, 2018.

BOOK CHAPTERS: 22

ABSTRACTS/POSTERS: 68

INVITED PRESENTATIONS: 44